Study to Evaluate the Safety, Efficacy, and Pharmacology of ARINA-1
Phase: 2a
Status: Ongoing
Details
RVN-301 – A Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacology of ARINA-1 administered twice daily by nebulizer in adult participants with non-cystic fibrosis bronchiectasis (NCFBE) with excess mucus and cough.
Sponsor: Renovion, Inc.
NCT05495243
